Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139763 · ClinicalTrials.gov registry record · Phase 3
US Inhaled Insulin Therapeutic Choice Questionnaire Study
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 740
- Enrollment target
- 20
- Study locations
NCT00139763 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Pfizer. The registered enrollment target is 740 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00139763, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 740 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments. This study will also ask if patients with uncontrolled type 2 diabetes currently managed on diabetes pills + once daily insulin will choose as the next treatment choice to take insulin multiple times a day if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.
Conditions Studied
Interventions
- PROCEDURE Educational Materials
Study Locations (20)
Arizona
- Pfizer Investigational Site - Chandler
- Pfizer Investigational Site - Mesa
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Tempe
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - San Diego
Delaware
- Pfizer Investigational Site - Newark
- Pfizer Investigational Site - Wilmington
Florida
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Jacksonville
Idaho
- Pfizer Investigational Site - Hayden
- Pfizer Investigational Site - Nampa
Colorado
- Pfizer Investigational Site - Colorado Springs
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Illinois
- Pfizer Investigational Site - Gurnee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00139763
The ClinicalTrials.gov registry entry for NCT00139763 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 740 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Educational Materials is the first listed.
NCT00139763 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Arizona, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT00139763 about?
NCT00139763 is a clinical study titled "US Inhaled Insulin Therapeutic Choice Questionnaire Study". This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhale...
What is the current status of trial NCT00139763?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 740 participants. The study started on 2005-07. Estimated completion is 2006-03.
What conditions does trial NCT00139763 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00139763?
The interventions under investigation include: Educational Materials (PROCEDURE).
Who is sponsoring clinical trial NCT00139763?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00139763 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.